0001516551-24-000043.txt : 20240304 0001516551-24-000043.hdr.sgml : 20240304 20240304195344 ACCESSION NUMBER: 0001516551-24-000043 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240229 FILED AS OF DATE: 20240304 DATE AS OF CHANGE: 20240304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Grayson Paul A. CENTRAL INDEX KEY: 0001861554 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-55136 FILM NUMBER: 24717697 MAIL ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Skye Bioscience, Inc. CENTRAL INDEX KEY: 0001516551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 450692882 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11250 EL CAMINO REAL, SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 410-0266 MAIL ADDRESS: STREET 1: 11250 EL CAMINO REAL, SUITE 100 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Emerald Bioscience, Inc. DATE OF NAME CHANGE: 20190325 FORMER COMPANY: FORMER CONFORMED NAME: Nemus Bioscience, Inc. DATE OF NAME CHANGE: 20141030 FORMER COMPANY: FORMER CONFORMED NAME: LOAD GUARD LOGISTICS, INC. DATE OF NAME CHANGE: 20121107 4 1 wk-form4_1709600012.xml FORM 4 X0508 4 2024-02-29 0 0001516551 Skye Bioscience, Inc. SKYE 0001861554 Grayson Paul A. C/O SKYE BIOSCIENCE, INC. 1250 EL CAMINO REAL SUITE 100 SAN DIEGO CA 92130 1 0 0 0 0 Common Stock 2024-02-29 4 A 0 100000 0 A 346252 D Stock Option (Right to Buy) 14.56 2024-02-29 4 A 0 35000 0 A 2034-03-01 Common Stock 35000 35000 D Represents a restricted stock unit ("RSU") award that vests on the following milestones: 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest upon achieving a market cap of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the RSUs will become fully vested. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024. /s/ Kaitlyn Arsenault, as Attorney-in-Fact 2024-03-04